Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in early Alzheimer's disease
NL-OMON54997Phase 3Active, not recruiting
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of blarcamesine in Alzheimer's disease (AD) (3 arms), sponsored by Anavex Life Sciences Corp. Primary endpoints: Change from baseline to week 48 in Alzheimer's Disease Assessment Scale-Cognition and Change from baseline to week 48 in Activities of Daily Living Scale. Started Aug 2020; status: active, not recruiting.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON54997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54997.